1-3 of 3
John Casey
Close
Sort by
Journal Articles

Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies

Deborah L White, Jacqueline A Rehn, Caitlin E Schutz, Susan L Heatley, Laura N Eadie, Ashlee Thomson, Elyse C Page, Michael Osborn, Shane Gangatharan, Ashley P Ng, Shaun Fleming, Pasquale Fedele, Toby Trahair, John Casey, Sally Mapp, Carol CY Cheung, Tasman Armytage, Michelle Henderson, Rosemary Sutton, Stephen Robert Larsen, Peter Presgrave, John Kwan, Samuel Bennett, Chun Yew Fong, Luciano Dalla-Pozza, David T Yeung, Matthew Greenwood
Journal: Blood
Blood (2023) 142 (Supplement 1): 1609.
https://doi.org/10.1182/blood-2023-178473
Published: 2023
Journal Articles

Blinatumomab in Combination with an Intensive Pediatric Protocol Results in High Rates of Day 79 MRD Negativity in Adolescent and Young Adult Acute Lymphoblastic Leukemia - Preliminary Results of the Australasian Leukaemia and Lymphoma Group (ALLG) ALL09 "Sublime” Study

Matthew Greenwood, Shane Gangatharan, Michael Philip Osborn, Ashley P Ng, Shaun Fleming, Pasquale Fedele, Toby Trahair, John Casey, Sally Mapp, Carol Cheung, Tasman Armytage, Michelle Henderson, Rosemary Sutton, Philip McCloud, Stephen R Larsen, Peter Presgrave, John Kwan, Samuel Bennett, Chun Yew Fong, Luciano Dalla Pozza
Journal: Blood
Blood (2022) 140 (Supplement 1): 8971–8972.
https://doi.org/10.1182/blood-2022-168568
Published: 2022
Journal Articles

Outcomes for Patients with Primary or Secondary Central System Lymphoma Treated with Ibrutinib: A Multicentre Retrospective Analysis

Katharine L Lewis, FRCPath, MRCP, MBBS, Kate Manos, MBBS, John Casey, FRACP,FRCPA,MBBS, Julie Crawford, MDMBBS,FRACP, Shir-Jing Ho, FRACP,FRCPA,MBBS, Samar Issa, FRACP, Andrew Grigg, Peter Wood, Maher K. Gandhi, PhD, Eliza A Hawkes, Chan Y. Cheah
Journal: Blood
Blood (2019) 134 (Supplement_1): 1620.
https://doi.org/10.1182/blood-2019-125730
Published: 2019